- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04409236
Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking
Randomized Trial of a Smartphone Application to Help Cancer Patients Stop Smoking (Quit2Heal)
Study Overview
Status
Intervention / Treatment
Detailed Description
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive the Quit2Heal app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
ARM II: Patients receive the QuitGuide app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
After randomization, patients are followed up at 3, 6, and 12 months.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Jonathan Bricker
- Phone Number: 877-250-6641
- Email: quit2heal@fredhutch.org
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- Recruiting
- Fred Hutch/University of Washington Cancer Consortium
-
Contact:
- Jonathan Bricker
- Phone Number: 877-250-6641
- Email: quit2heal@fredhutch.org
-
Principal Investigator:
- Jonathan Bricker
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 or older
- Diagnosed with cancer within the past 24 months or currently receiving or planning to receive cancer treatment in the next 3 months
- Smoked a cigarette (even a puff) in the past 30 days
- Interested in learning skills to quit smoking
- Willing to be randomly assigned to either smartphone application
- Live in the United States and will remain in the United States (US) for the next 12 months
- Have at least daily access to their own smartphone
- Know how to download a smartphone application
- Be willing and able to read English
- Not currently (i.e., within past 30 days) using other smoking cessation interventions
- Have never participated in our prior research trials
- Have never used the National Cancer Institute (NCI)'s QuitGuide app
- Being willing to complete a follow-up survey at 3, 6, and 12 months post-randomization
- Providing email, phone number(s), and mailing address
Exclusion Criteria:
- Currently (i.e., within past 30 days) using other smoking cessation interventions
- Has participated in our prior research trials
- Has used the NCI's QuitGuide app
- Not willing to complete a follow-up survey at 3, 6, and 12 months post-randomization
- Not providing email, phone number(s), and mailing address
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (Quit2Heal app)
Patients receive the Quit2Heal app and are encouraged to use it frequently.
During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
|
Ancillary studies
Use Quit2Heal app
Other Names:
|
Active Comparator: Arm II (QuitGuide app)
Patients receive the QuitGuide app and are encouraged to use it frequently.
During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
|
Ancillary studies
Use QuitGuide app
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with 30-day cigarette smoking cessation at 12 months.
Time Frame: At 12 months after randomization
|
No smoking at all in the past 30 or more days.
|
At 12 months after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with 30-day cigarette smoking cessation at 3 months.
Time Frame: At 3 months after randomization
|
No smoking at all in the past 30 or more days.
|
At 3 months after randomization
|
Number of participants with 30-day cigarette smoking cessation at 6 months.
Time Frame: At 6 months after randomization
|
No smoking at all in the past 30 or more days.
|
At 6 months after randomization
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jonathan Bricker, Fred Hutch/University of Washington Cancer Consortium
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RG1007577
- NCI-2020-03442 (Other Grant/Funding Number: CTRP (Clinical Trial Reporting Program))
- 10432 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
- R01CA253975 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Solid Neoplasm
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Canada
-
National Cancer Institute (NCI)RecruitingLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Puerto Rico
-
University of California, San FranciscoCompletedIntegrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced CancerAdvanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterTerminatedLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
Clinical Trials on Survey Administration
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Boston UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHepatocellular CarcinomaUnited States
-
Thomas Jefferson UniversityRecruitingMalignant Head and Neck NeoplasmUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingAcute Lymphoblastic LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | COVID-19 Infection | Recurrent Hematologic MalignancyUnited States
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States